CCL2 and non-small cell lung carcinoma: Notably, combined STAT3 inhibition and osimertinib effectively reversed resistance in xenografts.<h4>Conclusion</h4>These findings uncover a novel CCL2-STAT3-ZEB1 signaling axis that drives acquired osimertinib resistance in NSCLC.